Newsroom

Jan 13, 2021

Orphan Disease Treatment Institute Co., Ltd.:
The results summary of phase 1/2 clinical trial in Japan for DS-5141, which Daiichi Sankyo is jointly developing with the INCJ portfolio company, Orphan Disease Treatment Institute

Daiichi Sankyo Company, Limited today announced the results summary of the Phase 1/2 clinical trial in Japan of DS-5141 in patients with Duchenne muscular dystrophy, which Daiichi Sankyo is jointly developing with the INCJ portfolio company, Orphan Disease Treatment Institute Co., Ltd..

PDF(Press Releases)

Related Press Releases

Feb 25, 2016
INCJ announces additional investment in Orphan Disease Treatment Institute Co., Ltd.

Investment Information

HOME
About Us
Our Business
Newsroom
Our Investments